Cannabis over 50 — the knowledge hub on cannabis in older age

Older adults are one of the fastest-growing groups of medical cannabis users — and the most vulnerable. Altered liver function, multiple long-term medications, fall risk and multiple coexisting conditions demand a much more cautious approach than in younger adults. This hub gathers the evidence on pain, sleep, interactions with blood thinners and statins, fall and cognitive risk, and dementia — including honest reporting of negative trial results and a conservative titration guide.

Altered pharmacokinetics and organ function in old age

With increasing age, the human organism undergoes fundamental changes, which significantly influences the pharmacokinetics of cannabinoids. Since THC and CBD are highly lipophilic, i.e. fat-soluble, they accumulate in adipose tissue, which changes with age. At the same time, total body water content and muscle mass decrease. This leads to a prolonged half-life and delayed excretion of the active substances. Furthermore, the liver, which is responsible for degradation via the cytochrome P450 enzyme system, works less efficiently in old age. As a result, active substances and their metabolites remain in the bloodstream significantly longer than in younger patients.

This slowed elimination carries the risk of a gradual accumulation of the active substances with daily intake. Those affected often experience the effects with a delay, which can lead to a dangerous overdose if a subsequent dose is taken too quickly. Typical consequences in the daily lives of older people include pronounced daytime sleepiness, impaired responsiveness and cognitive irritation. Close monitoring of organ functions, especially liver and kidney values, is advisable before starting cannabinoid therapy. Dose adjustments must be made at significantly longer intervals to account for the sluggish metabolism.

Increased storage of cannabinoids in adipose tissue due to an altered ratio of muscle to fat mass.
Delayed degradation in the liver due to the age-related reduced activity of cytochrome P450 enzymes.
Risk of active substance accumulation with daily use, resulting in symptoms of overdose.
Need for longer intervals during dose escalation (titration) compared to younger individuals.

Legal framework and medical access in Switzerland

Access to medical cannabis in Switzerland has become much easier for older patients in recent years. Since August 2022, an exceptional licence from the Federal Office of Public Health (BAG) is no longer required. Doctors can prescribe corresponding preparations directly on a regular narcotics prescription. This significantly facilitates therapeutic support for chronic complaints in old age. Pharmacies are permitted to dispense magistral formulations or approved ready-to-use medicinal products, which guarantees controlled quality and standardised active substance concentrations. Illegal sources, on the other hand, pose incalculable risks due to contamination or fluctuating THC levels.

Despite the legal facilitation, cost coverage by the mandatory health insurance remains a hurdle. Health insurance funds usually only reimburse the therapy in justified individual cases upon request, which is why seniors often have to bear the costs themselves. Another critical point is participation in road traffic. In Switzerland, a strict zero-tolerance policy applies with a statutory THC limit of 1.5 micrograms per litre of blood. Since degradation is slowed down in old age, active drivers should definitely discuss the issue of fitness to drive in detail with their treating physician beforehand.

Facilitated access due to the elimination of the FOPH exceptional permit since August 2022.
Prescription is issued directly via a medical narcotics prescription for standardised preparations.
Cost coverage by health insurance is only granted on a case-by-case basis following prior cost assumption approval.
Strict road traffic law consequences due to the low blood THC limit of 1.5 micrograms per litre.

Multimorbidity and interactions with long-term medication

Many people over fifty take various medications daily due to multiple chronic conditions. This multimorbidity significantly increases the risk of dangerous interactions with cannabinoids. Both CBD and THC are broken down by the same liver enzymes that are also responsible for metabolising common cardiovascular preparations, blood thinners, and cholesterol-lowering drugs. Simultaneous intake can cause the concentration of these vital medications in the blood to rise or fall uncontrollably. This can impair the therapeutic effect or cause severe side effects of the regular long-term medication without those affected immediately recognising the cause.

The combination of cannabis with antihypertensive drugs or sedatives is particularly critical. Cannabinoids can acutely lower blood pressure, which can lead to dizziness when standing up quickly and thus to severe falls. The sedating effect of sleeping pills, antidepressants, or strong painkillers is also often unpredictably enhanced by cannabis. In case of uncertainty or acute symptoms of poisoning, the national emergency number of Tox Info Suisse provides professional support around the clock at 145. Complete disclosure of all substances taken to the medical profession is therefore essential for patient safety.

Influence on the breakdown of blood thinners and statins due to competition for liver enzymes.
Increased risk of falls due to orthostatic hypotension during simultaneous intake of blood pressure-lowering drugs.
Unpredictable enhancement of the depressant effect of sleeping pills, sedatives, and opioids.
Consultation option in case of suspected adverse interactions via the emergency number 145 of Tox Info Suisse.

FAQ

How does medical cannabis affect the risk of falls in old age?

Medical cannabis can increase the risk of falls in older people in several ways. THC negatively affects the sense of balance, motor coordination, and reaction time. In addition, it often leads to a sudden drop in blood pressure upon standing up, orthostatic hypotension, which causes dizziness. In combination with age-related muscle weakness or the use of sedatives, the risk of falls and subsequent injuries such as bone fractures increases significantly. Therefore, extremely cautious dosing in the evening directly before going to bed is advisable.

Can I drive a car in Switzerland despite therapy with medical cannabis?

Driving under the influence of cannabis is regulated extremely strictly by law in Switzerland. A de facto zero-tolerance limit of 1.5 micrograms of THC per litre of blood applies. Since metabolism is delayed in old age, this limit can still be exceeded days after the last intake. Anyone who consumes medical cannabis is generally deemed unfit to drive if THC is detected, unless a medical assessment confirms fitness to drive under stable medication in the individual case. However, the risk of driving licence revocation remains high.

Does Swiss health insurance pay for treatment with cannabis preparations in old age?

The costs of medical cannabis preparations are not automatically covered by the compulsory health insurance in Switzerland. They are not part of the standard benefits. Reimbursement only occurs in justified exceptional cases if other established therapies have failed or were not tolerated. To this end, the treating physician must submit a detailed request for cost assumption to the respective health insurance provider. The insurance company's medical consultant then reviews the individual case. Without this prior approval, patients must bear the costs themselves.